Bonnie Ky, MD, MSCE

faculty photo
Assistant Professor of Medicine
Department: Medicine

Contact information
Hospital of the University of Pennsylvania
11-105 Smilow Center for Translational Research
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-573-6606
Fax: 215-746-7415
Education:
BS (Chemical Engineering )
Massachusetts Institute of Technology, 1995.
MD (Medicine)
University of Pennsylvania, 2001.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2009.
Permanent link
 

Description of Research Expertise

Cardiotoxicity from cancer therapy is detectable, preventable and treatable. This is the focus of Dr. Ky’s research program. Cancer therapies are becoming increasingly effective at killing cancer, but these treatments also have toxic side effects, resulting in a growing population of cancer patients and survivors with heart disease. In our lab, we are studying innovative strategies to understand the changes in heart function that occur with common cancer therapies, and how we can apply these methods to understand an individual patient’s risk of developing heart disease and heart failure. Our goals are to bring these exciting research findings to the clinic and continue our mission of delivering state-of-the-art, evidence-based medicine to cancer patients and survivors regionally and nationally. We highlight 3 recent discoveries from our lab below.

How breast cancer therapy affects heart function. In a recent paper published in Circulation, we rigorously and comprehensively define the precise changes that occur with heart function over time in breast cancer patients treated with doxorubicin, trastuzumab and radiation. We found that with these cancer therapies, there are modest, but persistent declines in heart function, even at 3 years post treatment exposure. We also determined that afterload, or blood pressure, is a major determinant of this adverse remodeling. These findings might suggest that aggressive blood pressure control is critical in mitigating a patient’s risk of developing heart dysfunction. We have proposed new trials to test this hypothesis.

How innovative new imaging tools can predict heart damage with cancer therapy. We are also interested in discovering new strategies to predict the risk of subsequent heart damage in cancer patients. In two separate manuscripts published in the Journal of American College of Cardiology Imaging, we have used 2-dimensional and 3-dimensional ultrasound techniques in order to more precisely and deeply understand how the heart functions. We have discovered that early changes in 2D and 3D circumferential strain, or deformation, are associated with the risk of developing cardiotoxicity with anthracyclines.

How simple blood tests – using new markers – can predict heart damage with cancer therapy. We are also studying the role of new blood markers of oxidative stress – and how they can predict who will develop heart damage with anthracycline chemotherapy. These findings were published in the Journal of the American College of Cardiology. We are now testing in a clinical trial how these blood markers can be used to understand why statins might protect the heart and who may benefit the most from statins when receiving anthracycline chemotherapy.

Selected Publications

Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J: Clinical Trial Experience with CA4P Anticancer Therapy: Focus on Cardiovascular Adverse Events and Hypertension Management. Gynecologic Oncology Research 5(1), January 2018.

Brown J, Rickels M, Troxel A, Zemel B, Damjanov N, Ky B, Rhim A, Rustgi A, Courneya KS, Schmitz K: Dose-response effects of exercise on insulin among colon cancer survivors. Endocrine Related Cancer 25(1), Jan 2018.

Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, Elamm C, Lenihan DJ, Ky B.: Longitudinal Assessment of Vascular Function with Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Circulation Heart Failure 2018 Notes: Accepted for publication.

Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, Plappert T, Englefield V, Smith AM, Zhang C, Hundley WG, Ky B: Abnormalities in Three-Dimensional Left Ventricular Mechanics with Anthracycline Chemotherapy are Associated with Systolic and Diastolic Dysfunction. Journal of the American College of Cardiology Imaging 2018 Notes: Manuscript accepted, 2018.

DiLorenzo MP, Wang Y, Ky B, Elci O, Goldmuntz E, Mercer-Rosa L: Longitudinal Changes in Right Ventricular Function in Tetralogy of Fallot in the Initial Years after Surgical Repair Journal of the American Society of Echocardiography 2018 Notes: Manuscript accepted.

Narayan, V and Ky, B: Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. Annual Review of Medicine 69: 97-111, 2018.

Brown J, Damjanov N, Courneya KS, Troxel A, Zemel B, Rickels MR, Ky B, Rhim A, Rustgi A, Schmitz K : A Randomized Dose-Response Trial of Aerobic Exercise and Health-Related Quality of Life in Colon Cancer Survivors. Pscyho-Oncology 2018 Notes: Accepted for Publication.

Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, O'Quinn R, Cohen AD, Stadtmauer E, Ky B, Weiss BM.: Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-Analysis. JAMA Oncology Page: e174519, December 2017.

Truitt R, Mu A, Corbin EA, Vite A, Brandimarto J, Ky B, Margulies KB: Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model. JACC Basic Translational Science December 2017 Notes: Manuscript accepted for publication.

Zhao H, O’Quinn R, Ambrose M, Jagasia D, Ky B, Wald J, Ferrari V, Kirkpatrick J, and Han Y: Contrast Echocardiography Provides the Greatest Impact in Patients with Reduced Ejection Fraction. Journal of the American Society of Echocardiography October 2017 Notes: epub ahead of print.

back to top
Last updated: 05/31/2018
The Trustees of the University of Pennsylvania